HEART TRANSPLANTATION
Donor Organ Preservation in High-Risk Cardiac Transplantation
G. Faggian, A. Forni, and A. Mazzucco
ABSTRACT
Aim. To evaluate safety and efficacy of blood cardioplegia in a retrospective selected (but
not randomized) donor/recipient population as standard organ preservation technique in
high-risk heart transplants (HTX).
Materials and methods. The rationale of different strategies was based on both donor
and recipient evaluations. Unstable donors with a long history of well-known risk factors
and/or long-distance retrieval were given blood cardioplegia, particularly for HTX
candidates in poor preoperative clinical condition. Organ protection was performed by
administration of St Thomas II crystalloid cardioplegia in 74 patients (group 1) while 58
others (group 2) received blood cardioplegia.
Results. Groups I versus II shows comparable results for immediate postoperative
mortality rates (4% vs 7%, P = .4), high doses of inotropic drug support (48% vs 20%, P
= .08), and the need for postoperative mechanical assistance devices (9% vs 4.5%, P = .4).
In contrast statistically significant differences were observed for occurrence of acute right
ventricular failure (50% vs 5%; P = .004), atrioventricular conduction disturbances (63%
vs 10%, P = .003), spontaneous sinus rhythm recovery (18% vs 64% P = .0038) and
reperfusion interval (RI) (time between removal of aortic cross-clamp and discontinuation
of extracorporeal circulation (ECC)) exceeding 30 minutes (70% vs 21%, P = .0004).
Higher peak creatine kinase MB mean value (176 23 vs 90 19, P = .06) indicated more
severe ischemic damage among G1 patients.
Conclusion. This study suggests that high-risk heart transplant candidates benefit from
blood cardioplegia, due to the reduced incidence of both right ventricular failure and
severe cardiac arrhythmia. Potential limitations to this novel technique may be linked to
the higher expenses due to the need for a perfusion technician. Improved myocardial
protection can be seen even in a longitudinal study on chronic rejection: this form of
allograft protection may preserve the matrix and the endothelium.
H
EART TRANSPLANTATION (HTX) represents the
treatment of choice for end-stage cardiac diseases.
The present donor scarcity has led to new criteria for organ
selection. Acute graft failure is often linked to poor preop-
erative recipient clinical condition to a suboptimal donor
and morbid events in the immediate postoperative period.
1
Various methods of graft protection from ischemia have
been assessed in several papers.
2–4
Administration of blood
cardioplegia
5
has produced good results leading us to
employ it as a routine organ preservation technique for
From the Division of Cardiac Surgery, Piazzale Stefani 1,
Verona, Italy.
Address reprint request to Prof Giuseppe Faggian, Division of
Cardiac Surgery; Piazzale Stefani 12, 37126 Verona, Italy. E-
mail: Giuseppe.faggian@univr.it
© 2004 by Elsevier Inc. All rights reserved. 0041-1345/04/$–see front matter
360 Park Avenue South, New York, NY 10010-1710 doi:10.1016/j.transproceed.2004.02.049
Transplantation Proceedings, 36, 617– 619 (2004) 617